| Literature DB >> 35096534 |
Ihab Kamel1, Muhammad F Ahmed2, Anish Sethi2.
Abstract
Regional anesthesia is an integral component of successful orthopedic surgery. Neuraxial anesthesia is commonly used for surgical anesthesia while peripheral nerve blocks are often used for postoperative analgesia. Patient evaluation for regional anesthesia should include neurological, pulmonary, cardiovascular, and hematological assessments. Neuraxial blocks include spinal, epidural, and combined spinal epidural. Upper extremity peripheral nerve blocks include interscalene, supraclavicular, infraclavicular, and axillary. Lower extremity peripheral nerve blocks include femoral nerve block, saphenous nerve block, sciatic nerve block, iPACK block, ankle block and lumbar plexus block. The choice of regional anesthesia is a unanimous decision made by the surgeon, the anesthesiologist, and the patient based on a risk-benefit assessment. The choice of the regional block depends on patient cooperation, patient positing, operative structures, operative manipulation, tourniquet use and the impact of post-operative motor blockade on initiation of physical therapy. Regional anesthesia is safe but has an inherent risk of failure and a relatively low incidence of complications such as local anesthetic systemic toxicity (LAST), nerve injury, falls, hematoma, infection and allergic reactions. Ultrasound should be used for regional anesthesia procedures to improve the efficacy and minimize complications. LAST treatment guidelines and rescue medications (intralipid) should be readily available during the regional anesthesia administration. ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.Entities:
Keywords: Adductor canal; Ankle; Axillary; Block failure; Brachial plexus; Combined spinal epidural; Complication; Continuous nerve block catheters; Epidural; Fascia iliaca; Femoral; Infraclavicular; Interscalene; Local anesthetic systemic toxicity; Lower extremity; Lumbar plexus; Nerve injury; Neuraxial blocks; Orthopedic surgery; Peripheral nerve blocks; Popliteal; Regional anesthesia; Saphenous; Sciatic; Spinal; Supraclavicular; Upper extremity; iPACK
Year: 2022 PMID: 35096534 PMCID: PMC8771411 DOI: 10.5312/wjo.v13.i1.11
Source DB: PubMed Journal: World J Orthop ISSN: 2218-5836
American Society of Regional Anesthesia guidelines for anticoagulant and antiplatelet drugs
|
|
|
|
|
|
| Anticoagulants for venous thromboembolism prophylaxis | ||||
| Enoxaparin (Lovenox); prophylaxis, once daily | 12 h | ≥ 12 h | ≥ 12 h | 4 h |
| Enoxaparin (Lovenox); prophylaxis, b.i.d. | 12 h | Contraindicated while catheter in place | 4 h | |
| Heparin SQ; prophylaxis; low-dose, b.i.d. and t.i.d. | 4-6 h | Immediately | 4-6 h | Immediately |
| Heparin SQ; prophylaxis; higher-dose, b.i.d. and t.i.d. | 12 h and assessment of coagulation status | Safety of indwelling catheters has not been established for doses > 5000 Units SQ or total daily dose > 15000 Units SQ. Risk/benefit assessment required | Immediately | |
| Dalteparin (Fragmin); prophylaxis, once daily | 12 h | ≥ 12 h | 12 h | 4 h |
| Anticoagulants at therapeutic doses | ||||
| Heparin IV; full Dose | 4-6 h and normal coagulation status | 1 h, with close monitoring | 4-6 h and normal coagulation status | 1 h |
| Heparin SQ; therapeutic dose | 24 h and assessment of coagulation status | Contraindicated while catheter in place | Immediately | |
| Enoxaparin (Lovenox); therapeutic dose | 24 h, consider checking anti-factor Xa level | Contraindicated while catheter in place | 4 h | |
| Apixaban (Eliquis) | 72 h | Contraindicated while catheter in place | 6 h | |
| Rivaroxaban (Xarelto) | 72 h | Contraindicated while catheter in place | 6 h | |
| Warfarin (Coumadin) | 5 d and normal INR | Variable instructions regarding management of catheter | Immediately | |
| Anti-platelet medications | ||||
| NSAID’s | No restrictions, may increase risk of bleeding | |||
| Aspirin | No restrictions, may increase risk of bleeding | |||
| Plavix | 5-7 d | 24 h postoperatively; catheter may be maintained for 1-2 d due to delayed antiplatelet effect | Immediately if no loading dose given | |
| Ticlodipine (Ticlid) | 10 days | 24 h postoperatively; catheter may be maintained for 1-2 d due to delayed antiplatelet effect | Immediately if no loading dose given | |
| Ticagrelor (Brillinta) | 5-7 d | Contraindicated while catheter in place | Immediately if no loading dose given | |
NSAID: Non-steroidal anti-inflammatory drug.
Summary of upper extremity peripheral nerve blocks
|
|
|
|
|
|
|
|
| Interscalene nerve block | Surgeries involving the shoulder, proximal aspect of humerus and the distal aspect of the clavicle | (1) Brachial plexus:C5 to C7; and (2) Cervical plexus: Supraclavicular nerve (C3 and C4) | LA injected between anterior and middle scalene muscles lateral to carotid artery and internal jugular vein | (1) Easy to perform; and (2) Comfortable for the patient | (1) Hemidiaphragmatic paralysis leading to respiratory compromise in patients with severe COPD; and (2) Not sufficient for elbow, forearm or hand surgeries | (1) Phrenic nerve palsy (100%); (2) Horner syndrome; and (3) Hoarseness |
| Supraclavicular nerve block | Surgery of the arm, elbow, forearm and hand. Extension into the interscalene area can cover shoulder procedures | C5-T1 | LA injected above the clavicle between anterior and middle scalene muscles at the level of the first rib, where the subclavian artery crosses over it | (1) Fast onset; (2) Easier to perform; and (3) Comfortable for the patient | Relatively higher incidence of pneumothorax | (1) Pneumothorax; (2) Phrenic nerve palsy; and (3) Hoarseness |
| Infraclavicular nerve block | Surgery of the arm, elbow, forearm and hand | C5-T1 | LA injected around the axillary artery below the clavicle, medial to coracoid process | Good choice for catheter placement | (1) Deeper block to perform; and (2) Greater discomfort during block placement | Pneumothorax (relatively low incidence) |
| Axillary nerve block | Surgery of the elbow, forearm and hand | Median nerve, ulnar nerve, radial nerve, and musculocutaneous nerve | LA injected around the axillary artery at the medial aspect of proximal arm | (1) Easy to perform; and (2) Low complication rate | (1) Often spares the musculocutaneous nerve; and (2) Requires arm abduction | (1) Hematoma formation; and (2) Intravascular injection |
COPD: Chronic obstructive pulmonary disease.
Summary of lower extremity peripheral nerve blocks
|
|
|
|
|
|
|
|
| Femoral nerve(Femoral nerve block) | Surgeries involving anterior aspect of the thigh and medial aspect of the leg below the knee | Femoral nerve | Inguinal crease; located lateral to femoral artery | (1) Broad coverage; and (2) Easily identifiable landmarks | Causes quadriceps weakness which may lead to falls | (1) LE weakness and falls; (2) Bleeding; (3) Infection; and (4) Nerve damage |
| Femoral nerve (Fascia Iliaca block) | Surgeries involving anterior aspect of the thigh and medial aspect of the leg below the knee | (1) Femoral nerve; and (2) Lateral femoral cutaneous nerve of the thigh | Inguinal crease, LA injected under fascia iliaca | (1) Easily identifiable landmarks; and (2) Assist in optimal patient positioning for spinal anesthesia | (1) Causes quadriceps weakness which may lead to falls; and (2) Large volume of local anesthetic required | (1) LE weakness and falls; (2) Bleeding; (3) Infection; and (4) Nerve damage |
| Sciatic nerve (Anterior, transgluteal, and subgluteal approaches) | Surgeries involving foot, ankle, and posterior knee | Sciatic nerve | Variable, based on injection site | (1) Broad lower extremity coverage; and (2) Easilyidentifiable landmarks | Motor blockade | (1) Bleeding; (2) Infection; and (3) Nerve damage, persistent foot drop and heel ulcers |
| Sciatic nerve (Popliteal Block) | Surgeries involving foot, ankle, posterior knee | Sciatic nerve | Popliteal fossa, located cephalad to the knee near popliteal artery | (1) Broad lower extremity coverage; and (2) Easilyidentifiable landmarks | Motor blockade | (1) Bleeding; (2) Infection; and (3) Nerve damage, persistent foot drop and heel ulcers |
| Saphenous nerve (Femoral triangle, medial femoral condyle, tibial tuberosity approaches) | Surgeries involving medial aspect of knee, foot, and ankle | Saphenous nerve | Variable, based on injection site | Motor-sparing | Does not provide anesthesia and analgesia to the posterior capsule of knee | (1) Bleeding; (2) Infection; and (3) Nerve damage - Potential lower extremity weakness at high doses |
| Saphenous nerve (Adductor Canal block) | Surgeries involving medial aspect of knee, foot, and ankle | (1) Saphenous nerve; and (2) Nerve to vastus medialis (branch of femoral nerve) | Medial thigh, located deep to the sartorius muscle, adjacent to the femoral artery and vein. | Motor-sparing | (1) Does not provide anesthesia and analgesia to the posterior capsule of knee; and (2) Compared to femoral nerve block, it is less efficacious for analgesia after ACL reconstruction surgery | (1) Bleeding; (2) Infection; (3) Nerve damage; and (4) Potential lower extremity weakness at high doses |
| iPACK | Surgeries involving the posterior knee capsule | Articular branches of the tibial, common peroneal, and obturator nerve to the posterior aspect of the knee | Popliteal crease, located cephalad to femoral condyles | Motor-sparing, increased posterior knee coverage | Coverage only to posterior knee; useful as an adjunct to alternative blocks | Inadvertent motor block due to local anesthetic spread to sciatic nerve branches |
| Ankle | Foot surgery | Saphenous, sural, posterior tibial, superficial peroneal, and deep peroneal nerves | Ankle and foot bony landmarks | Injection based on surface landmarks, no requirement for ultrasound | Limited efficacy for surgery proximal to the foot, potential higher failure rate due to blind technique | (1) Bleeding; (2) Infection; and (3) Nerve damage |
| Lumbar plexus | Hip surgery | Lumbar plexus, providing blockade to femoral, obturator, and lateral femoral cutaneous nerves | Lateral to lumbar spine, located cephalad to iliac crest | Coverage of multiple nerves with a single block | High potential for complications and block failure, technically challenging block to perform | (1) Bleeding and hematoma; (2) Infection; (3) Nerve damage; (4) Epidural spread resulting in high neuraxial anesthesia; (5) Hypotension, and (6) LAST |
ACL: anterior cruciate ligament; LAST: local anesthetic systemic toxicity.
Clinical presentation and management of local anesthetic systemic toxicity
|
|
|
|
| 1 Dizziness, drowsiness, tinnitus, perioral numbness |
| 2 Muscle twitching and tremors |
| 3 Seizures |
| 4 CNS depression, coma |
| 5 Hypertension, tachycardia |
| 6 Myocardial depression, ventricular arrhythmias, conduction delays |
| 7 EKG changes: Prolonged PR, QRS; T-wave changes |
| 8 Cardiovascular collapse |
|
|
| 1 Call for help |
| 2 Call for LAST rescue kit |
| 3 Consider early lipid emulsion administration |
| (1) Under 70 kg: Bolus 1.5 mL/kg over 2-3 min, Infuse 0.25 mL/kg/min. Repeat bolus or double the infusion rate if the patient remains unstable |
| (2) Over 70 kg: Bolus approximately 100 mL over 2-3 min, infuse approximately 250 mL over 15-20 min. Repeat bolus or double the infusion rate if the patient remains unstable |
| (3) If the patient is stable, continue lipid emulsion ≥ 15 min after hemodynamic stability. Maximum lipid dose: 12 mL/kg |
| 4 Seizure |
| (1) Airway management |
| (2) Benzodiazepine |
| (3) Consider low dose propofol |
| 5 Arrhythmia or cardiovascular Instability |
| (1) Epinephrine: Administered at lower dose than ACLS dosing, start with ≤ 1 mcg/kg |
| (2) Avoid local anesthetics, beta-blockers, vasopressin, calcium channel blockers |
| (3) Consider alerting cardiopulmonary bypass team |
| 6 Close monitoring |
| Once stable, continue close monitoring: 2 h after seizure, 4-6 h after cardiovascular instability, and as clinically appropriate after cardiac arrest |
EKG: Electrocardiogram; CNS: Central nervous system.